Jason Rhodes is a partner and focuses on creating and building novel therapeutics companies.
Jason is the chairman and was the founding CEO of Generation Bio (NASDAQ: GBIO) and Dyne Therapeutics (NASDAQ: DYN). He is also on the boards of Replimune (NASDAQ: REPL), Gemini Therapeutics (NASDAQ: GMTX), Accent Therapeutics, Be Biopharma, K36, Rectify Pharmaceuticals, and Third Harmonic Bio. He was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020.
Previously, Jason held leadership positions at Epizyme (NASDAQ: EPZM), where he was President and built the company from early stage research into the clinic and through a successful IPO in 2013, and at Alnylam Pharmaceuticals (NASDAQ: ALNY), where he led business development. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer.
Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council. Jason spends his free time mountain biking and loudly watching Spanish fútbol with his family.